dabigatran has been researched along with Hemophilia A in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ragni, MV | 1 |
| Debasse, M; Jacquemin, M; Peerlinck, K; Peetermans, M; Schoeters, J; Toelen, J; van Horenbeeck, I; van Ryn, J; Vanassche, T; Vanlinthout, I; Verhamme, P | 1 |
| Smith, LL | 1 |
| Hart, C; Schmid, S | 1 |
| Brunner, K; Ehrenschwender, M; Koessler, J; Steigerwald, U | 1 |
2 review(s) available for dabigatran and Hemophilia A
| Article | Year |
|---|---|
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes | 2013 |
[Coagulation disorders in the intensive care unit - what is new?].
Topics: Anticoagulants; Dabigatran; Hemophilia A; Hemorrhage; Heparin; Humans; Intensive Care Units; Rivaroxaban; Thrombocytopenia; Thrombosis; Warfarin | 2016 |
3 other study(ies) available for dabigatran and Hemophilia A
| Article | Year |
|---|---|
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
Topics: Activated Protein C Resistance; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibody Specificity; Antithrombins; Blood Coagulation Disorders; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Immunologic; False Negative Reactions; False Positive Reactions; Hemophilia A; Humans; Lupus Coagulation Inhibitor | 2015 |
ISTH 2015 Congress.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroscopy; Blood Loss, Surgical; Dabigatran; Factor VIII; Hemophilia A; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Single-Domain Antibodies; Venous Thromboembolism | 2015 |
A 77-year-old man with a prolonged activated partial thromboplastin time.
Topics: Aged; Anticoagulants; Autoantibodies; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male; Partial Thromboplastin Time | 2012 |